Study population: Patients attending the Out Patient Department and admitted to Institute of Liver and Biliary Sciences.

Study design: Prospective randomized controlled trial Study period: One year- January 2017- December 2018 Sample size: 130 (65 cases in each group) Intervention: The subjects will be given Fecal Microbiota Transplantation through a NJ tube placed after admission to the hospital. Participants will be administered the processed fecal microbiota sample collected from a related or unrelated healthy donor for a period of 7 days.

Monitoring and assessment:

The recipient will be monitored every day after Fecal Microbiota Transplantation therapy.

The recipient will undergo physical examination, complete blood counts, at baseline and a chest X ray, serum procalcitonin, CRP and Tumor Necrosis Factor alpha levels, Liver Function Tests, Kidney Function Tests, International Normalized Ratio and arterial ammonia, at day 0,4,7,14,28,90,180,270 and 365 from the start of therapy.

Microbiota analysis of the donors will be done at baseline and the recipients will be done on day 0,7,28,90 & 180.

Inclusion Criteria:

• Patients with severe alcoholic hepatitis .
• Eligible for steroid therapy.

Exclusion Criteria:

• Upper gastrointestinal bleed within the past one month.
• Active sepsis
• Serum creatinine > 1.5 mg/dl (Hepato renal syndrome)
• Intestinal paralysis
• Hepatic or extrahepatic malignancy
• Disseminated intravascular coagulation
• Discriminant Function (DF) >90